Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

2015; Oxford University Press; Volume: 10; Issue: 2 Linguagem: Inglês

10.1093/ecco-jcc/jjv220

ISSN

1876-4479

Autores

K Gecse, Barbara D. Lovász, Klaudia Farkas, János Banai, László Bene, Beáta Gasztonyi, Petra A. Golovics, Tünde Kristóf, Péter L. Lakatos, Á Csontos, Márk Juhász, Ferenc Nagy, Károly Palatka, Mária Papp, Árpád V. Patai, Lilla Lakner, Á Salamon, Tamás Szamosi, Zoltán Szepes, Gábor Tamás Tóth, Áron Vincze, Balázs Szalay, Tamás Molnár, Péter L. Lakatos,

Tópico(s)

Inflammatory Bowel Disease

Resumo

Background and Aims:Biosimilar infliximab CT-P13 is approved for all indications of the originator product in Europe. Prospective data on its efficacy, safety, and immunogenicity in inflammatory bowel diseases are lacking.

Referência(s)